NUCANA PLC-ADR (NCNA)

US67022C2052 - ADR

1.28  -0.05 (-3.76%)

Premarket: 1.3 +0.02 (+1.56%)

Fundamental Rating

1

NCNA gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 565 industry peers in the Biotechnology industry. NCNA has a bad profitability rating. Also its financial health evaluation is rather negative. NCNA is valued expensive and it does not seem to be growing.



0

1. Profitability

1.1 Basic Checks

NCNA had negative earnings in the past year.
NCNA had a negative operating cash flow in the past year.
NCNA had negative earnings in each of the past 5 years.
NCNA had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

The Return On Assets of NCNA (-140.43%) is worse than 83.60% of its industry peers.
NCNA has a Return On Equity of -741.68%. This is amonst the worse of the industry: NCNA underperforms 82.17% of its industry peers.
Industry RankSector Rank
ROA -140.43%
ROE -741.68%
ROIC N/A
ROA(3y)-68.88%
ROA(5y)-53.12%
ROE(3y)-110.2%
ROE(5y)-79.05%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for NCNA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

1

2. Health

2.1 Basic Checks

Compared to 1 year ago, NCNA has more shares outstanding
Compared to 5 years ago, NCNA has more shares outstanding
Compared to 1 year ago, NCNA has a worse debt to assets ratio.

2.2 Solvency

Based on the Altman-Z score of -15.20, we must say that NCNA is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of NCNA (-15.20) is worse than 82.17% of its industry peers.
NCNA has a Debt/Equity ratio of 0.04. This is a healthy value indicating a solid balance between debt and equity.
NCNA has a Debt to Equity ratio of 0.04. This is in the lower half of the industry: NCNA underperforms 60.25% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.04
Debt/FCF N/A
Altman-Z -15.2
ROIC/WACCN/A
WACCN/A

2.3 Liquidity

NCNA has a Current Ratio of 1.08. This is a normal value and indicates that NCNA is financially healthy and should not expect problems in meeting its short term obligations.
NCNA's Current ratio of 1.08 is on the low side compared to the rest of the industry. NCNA is outperformed by 87.17% of its industry peers.
A Quick Ratio of 1.08 indicates that NCNA should not have too much problems paying its short term obligations.
The Quick ratio of NCNA (1.08) is worse than 85.20% of its industry peers.
Industry RankSector Rank
Current Ratio 1.08
Quick Ratio 1.08

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 17.46% over the past year.
EPS 1Y (TTM)17.46%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-20%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 24.99% on average over the next years. This is a very strong growth
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y13.3%
EPS Next 2Y19.49%
EPS Next 3Y23.99%
EPS Next 5Y24.99%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for NCNA. In the last year negative earnings were reported.
Also next year NCNA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as NCNA's earnings are expected to grow with 23.99% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y19.49%
EPS Next 3Y23.99%

0

5. Dividend

5.1 Amount

No dividends for NCNA!.
Industry RankSector Rank
Dividend Yield N/A

NUCANA PLC-ADR

NASDAQ:NCNA (11/20/2024, 8:00:01 PM)

Premarket: 1.3 +0.02 (+1.56%)

1.28

-0.05 (-3.76%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap2.90M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -140.43%
ROE -741.68%
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM N/A
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.04
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 1.08
Quick Ratio 1.08
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)17.46%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y13.3%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y